This Market Spotlight report covers the Basal Cell Carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

• The approved drugs in the basal cell carcinoma space target the immune system, thymidylate synthase, reactive oxygen species/free radicals, programmed death-1 receptor, programmed death ligands (PD-L1 and PD-L2), and Hedgehog signaling pathway. These therapies are administered via the topical, oral, and intravenous routes.
• The majority of industry-sponsored drugs in active clinical development for basal cell carcinoma are in Phase II. Therapies in the pipeline for basal cell carcinoma focus on a wide variety of targets. These drugs are administered via the topical, intratumoral, intravenous, subcutaneous, intradermal, and oral routes.
• High-impact upcoming events for drugs in the basal cell carcinoma space comprise topline Phase III trial results for Ameluz and Patidegib Gel, and topline Phase II trial results for MW005.
• The overall likelihood of approval of a Phase I solid tumors asset is 5.1%, and the average probability a drug advances from Phase III is 41.6%. Drugs, on average, take 9.9 years from Phase I to approval in the solid tumors space, as well as in the overall oncology space.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for basal cell carcinoma have been in the early and mid-phases of development, with 86% of trials in Phase I–II, and only 14% in Phase III–IV.
• The US has a substantial lead in the number of basal cell carcinoma clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
• Clinical trial activity in the basal cell carcinoma space is dominated by completed trials. Roche has the highest number of completed clinical trials for basal cell carcinoma, with 18 trials.
• Roche leads industry sponsors with the highest overall number of clinical trials for basal cell carcinoma, followed by Novartis.